ABSTRACT. Changes in the normal hormonal regulation of linear growth which lead to growth failure in children with chronic renal failure (CRF) are not well understood. Previous studies indicate that serum levels of growth hormone and IGF-I and I1 are normal or elevated in this population; and that serum levels of poorly defined inhibitors of IGF action are increased. Using a recently developed RIA for the 25-kD IGF-binding protein (IGF-BP25), we report significant elevations of this protein in children with CRF when compared to age-and sex-matched controls. IGF-BP25 levels correlate positively with IGF-binding activity in both populations, indicating that the RIA reflects levels of bioactive protein. Although the variation of serum IGF-BP25 with chronologic age and IGF levels are preserved in CRF, the quantitative interrelationships are disrupted. Levels of the 53-kD IGF-binding protein, an IGFbinding protein derived from the high mol wt IGF complex, were also found to be elevated in the CRF population and, unlike in the control population, did not vary with age or IGF levels. IGF-BP25 has been shown to inhibit IGF mitogenic action in vitro. Our finding of elevated levels of IGF-BP25 in children with CRF suggests that this protein may play a role in the growth retardation of pediatric chronic renal failure. The significance of the elevated IGF-BP53 levels in CRF remains uncertain. (Pediatr Res 26:308-315, 1989) 
IGF-BP25 in children with CRF suggests that this protein may play a role in the growth retardation of pediatric chronic renal failure. The significance of the elevated IGF-BP53 levels in CRF remains uncertain. (Pediatr Res 26:308-315, 1989) Abbreviations CRF, chronic renal failure IGF-BP25, 25 kD IGF binding protein IGF-BP53, 53 kD IGF binding protein IGF-I and 11, also known as the somatomedins, are peptides that mediate the mitogenic actions of growth hormone (7) . Serum IGF-I levels are normal in children with CRF, whereas IGF-I1 levels are elevated (8) .
Both IGF-I and IGF-I1 circulate in the serum tightly complexed to specific binding proteins (9) . Most of the serum IGF is present in a 150-200 kD serum fraction that may, in part, be covalently complexed (10) . The major portion of unsaturated IGF-binding activity is found in a 30-50-kD fraction, whereas unbound IGF is undetectable in serum. Previous studies have shown that association of IGF with an unsaturated IGF-binding protein preparation inhibits the cellular metabolic actions of IGF (1 1).
It has been postulated that the low mol wt unsaturated IGFbinding protein may function as a growth inhibitor in CRF. Elevated levels of unsaturated IGF-binding activity have been identified in the sera of adults and children with CRF (12, 13) , and levels of the low mol wt IGF-binding protein measured by RIA are elevated in adults with diabetic nephropathy (14) . Limited data indicate that IGF-BP25 levels are also elevated in children with CRF (15) .
We have recently isolated and characterized the cDNA for the low mol wt unsaturated IGF-binding protein (IGF-BP25) isolated from the Hep-G2 human hepatoma cell line (16) . This protein, which has a predicted M, of 25.274 kD, appears to be identical to the low mol wt unsaturated IGF-binding protein isolated from placenta (1 7) and amniotic fluid (1 5) . Using a recently developed RIA, we demonstrate that serum IGF-BP25 levels are elevated in children with chronic renal failure as compared to agematched controls. These data support the hypothesis that alterations in IGF binding proteins may play a role in the growth retardation associated with pediatric CRF.
Compromised linear growth is a frequent complication of CRF in childhood (I). The factors that contribute to this growth retardation have not been well defined. Nutritional therapy and treatment of renal osteodystrophy and acidosis can lead to an improved growth rate; however, normalization of linear growth is rarely achieved (2, 3) . This growth failure occurs in the presence of elevated growth hormone levels (4) and a probable euthyroid state (5, 6) .
MATERIALS AND METHODS
Sample collection. The study population, described in a previous report (8) , consisted of 16 children with endstage renal failure and 16 age-and sex-matched healthy controls aged 1 to 14.5 y. Biochemical characteristics of the children with CRF include: serum urea = 8 1 k 26 mg/100 mL (mean k SD), serum creatinine = 5.9 + 2.7 mg/100 mL, serum bicarbonate = 23 11: 4 mEq/L, and GFR = 10 11: 7 mL/min/1.73 m2. None of the subjects was on glucocorticoid therapy at the time of sampling. For the CRF population, ht and growth velocities averaged -3.7 a 1.6 and -1.9 11: 1.8 SD below the means for chronologic age, respectively. All of the children with CRF had either a ht or growth velocity >2 SD below the mean for chronologic age, or both. The matched controls had normal heights (between 5th and 95th centiles) for chronologic age. All study subjects were prepubertal.
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Fasting morning (0800-1 100 h) blood samples were collected for routine clinical testing, and sample residuals were used for this study. Blood samples were collected in nonheparinized syringes, allowed to clot, and the serum was stored at -70°C until use. RIA. The IGF-BP25 RIA was performed using a polyclonal antiserum from rabbits immunized with purified Hep-G2 human hepatoma cell-derived IGF-BP25 with a highly purified monophosporyl lipid A/trehalose dimycolate adjuvant (RIB1 ImmunoChem Research, Inc., Hamilton, MT). The assay buffer was Dulbecco's PBS, pH 7.4, 0.1% BSA. A total of 0.1 mL of sample or standard and 100 pL of antiserum at a 1 : 1000 dilution in assay buffer were incubated for 1 h at room temperature. Fifty pL of ['251]IGF-BP (-5-10 K cpm) was then added, and the samples incubated for 18 h at 4°C. A total of 1.0 mg of agaroseimmobilized affinity-purified goat antirabbit IgG was then added for 3 h at room temperature. Bound counts in the pellet, obtained by centrifugation, were then determined in an automatic 7-counter. Standards were purified IGF-BP25 diluted in assay buffer, initially quantified by A2*0 against an ovalbumin standard (due to the small amount available) and later confirmed by comparison to a standard quantified by dry wt, which revealed superimposable displacement curves. Purity of both lots of purified IGF-BP25 used for standards were confirmed by N-terminal amino acid analysis. Nonspecific binding was determined in the presence of 100 pL of Hep-G2 human hepatoma cell conditioned medium containing 20-30 pg/mL of IGF-BP25.
IGF-BP25 RIA data were analyzed using the IBM-PC RIA Data Reduction program (M.L. Jaffe and Assoc., Silver Spring, MD), which uses a 4-parameter logistic model originally described by Rodbard (19) . All samples were assayed in duplicate and in serial dilution. Interassay coefficient of variation averaged 17.30 k 1.36 SD and intraassay coefficient of variation was estimated at 13.38 + 3.84% at 7.86 ng/mL. The detection range for the IGF-BP25 RIA was approximately 1-200 ng/mL or 0. l-20 ng/assay tube, with a total % specific binding of 20-30%.
Levels of IGF-BP53 were determined by RIA as previously described (20) . As previously reported, this assay has inter-and intraassay coefficients of variation equal to 14.5% at 6.3 pg/mL and 5.5% at 5.7 pg/mL; with a range of 0.1 to 20 ng/tube. IGF- I and I1 levels for the pediatric CRF subjects and their age-related controls were determined after acidification and Sephadex G-50 size-exclusion chromatography of the samples. Unsaturated IGFbinding activity was determined by a charcoal-separated ligand binding assay (8) . The IGF-I, IGF-11, and unsaturated IGFbinding activity data for these subjects have been previously published (8) .
Data analysis. Data were analyzed using Microstat-11, v.1.5 (Ecosoft, Inc., Indianapolis, IN) on a Leading Edge model D2 personal computer. Descriptive statistics are expressed as the arithmetic mean and SD. Median and range values are also given for the nonnormal data. Differences between groups were analyzed using the Wilcoxon two-sample rank-sum test. Correlations of variables within groups were calculated by regression analysis. IGF-I and I1 and IGF-BP25 levels have been observed to follow a log-normal distribution for normal children; therefore, these values were log transformed for regression analysis. Log-normalization of the IGF-BPS3 values had little effect on the correlative analysis. For data presentation in Figures 1-6 , data that were lognormalized for analysis are plotted against a log axis according to the actual measured values. Results were considered statistically significant for p < 0.05.
RESULTS

IGF-BP25
RIA charactevistics. The IGF-BP25 RIA, which we have not previously reported, has the following characteristics; freshly iodinated ['251]IGF-BP25 typically showed two major peaks of immunoreactivity after chromatography on a calibrated 0.9 x 100 cm Sephadex G-75 column. Total %B was approximately 50% more for peak 2 (-29 kD) than for peak 1(-43 kD).
Peak 1 may represent dimerized protein, although this was not directly shown. Peak 2 was used for the RIA.
To determine tracer stability in serum, -lo8 cpm aliquots of previously unchromatographed [1251]IGF-BP25 in assay buffer were incubated with 50 pL of buffer, uremic serum, or normal serum in a total volume of 0.5 mL for 1 h at room temperature, followed by a 30 min incubation at 37°C. The samples were then applied to a precalibrated 0.9 x 100 cm Sephadex G-75 column and eluted at 1 mL/min with collection of 1.25-mL fractions. There was no evidence for tracer degradation, because the elution patterns were the same for all three preincubation conditions. In a separate assay, unchromatographed [1251]IGF-BP25 preincubated under similar conditions was found to bind with similar affinity to the anti-IGF-BP25 antiserum.
As shown in Figure la , preincubation of IGF-BP25 with 500 ng/mL IGF-I (45 min, room temperature) had no effect on the displacement curve. Figure 1 b demonstrates the parallelism of both normal and uremic serum when compared to the purified standard. The antiserum is species specific, with sera from fetal 
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Serum fractions were assayed to determine the size distribution of the immunoreactive moieties. Normal and uremic serum pools (1 mL) were applied to a calibrated 75 mL S-300 gel column and eluted at 5 mL/h in 50 mmol sodium phosphate, pH 7.0,O. 1 M NaC1. The mean IGF-BP25 levels for the individual samples pooled for this assay were 1550 k 742 ng/mL for the uremic pool, and 352 f 314 ng/mL for the normal pool. As shown in Figure lc , a single major immunoreactive peak roughly corresponds to the expected mol wt calibration range.
IGF-BP25 levels. The levels of IGF-BP25 determined by RIA correlated with unsaturated binding activity determined by the charcoal-separated ligand-binding assay (r = 0.88, p = 2 x lo-"), suggesting that the two assays quantify identical proteins (Fig.  Id) . This correlation was consistent for the CRF patients (r = 0.84, p = 0.00004) and the matched controls (r = 0.74, p = 0.001).
Average IGF-BP25 levels were significantly higher for the CRF children (3576 f 6584 ng/mL, median 1279 ng/mL, range 294-27,225 ng/mL) as compared to the controls (403 k 264 ng/mL, median 364 ng/mL, range 64-93 1 ng/mL), and IGF-BP25 levels were significantly higher for the CRF subject in each matched pair. As shown in Figure 2a , an age-related negative trend for immunoassayable IGF-BP25 levels was observed for the controls (r = -0.76, p = 0.0006) and for the children with CRF (r = -0.56, p = 0.02).
To examine the possibility that the increased IGF-BP25 levels in CRF were related to a delay in gonadal hormone maturation, levels for the four CRF children above the age of 10 y were compared with four sex-matched controls between 7 and 9 y of age. The levels for the CRF children were significantly elevated relative to the younger controls. Unfortunately, sex steroid levels were not directly measured for the study subjects. IGF-BP25 levels did not correlate with nutritional intake (percent recommended daily allowance) for the I 1 CRF children who provided written dietary histories (r = -0.002, p = 0.99).
IGF-BP53 levels. IGF-BP53 levels were significantly elevated for the CRF children (4.60 f 1.06 j~g/mL) as compared to controls (2.59 k 0.68 jLg/mL). As shown in Figure 2b , the IGF-BP53 levels showed a positive correlation with age for the control children (r = 0.75, p = 0.001), but not for the children with CRF (r = 0.05, p = 0.8). IGF-BP53 levels showed a negative correlation with IGF-binding activity for the controls (r = -0.59, p = 0.03) but not for the CRF children (r = -0.10, p = 0.70).
IGF-I and IGF-11 levels. For both study groups, log-normal IGF-I and IGF-I1 levels positively correlated with age (Figs 3a and b). As previously reported (8), no significant difference for IGF-I levels between the children with CRF (220 f 182 ng/mL, median 156 ng/mL, range 45-753 ng/mL) and their matched controls (248 f 155 ng/mL, median 268 ng/mL, range 60-5 10 ng/mL) was observed. However, IGF-I1 levels were significantly elevated for the CRF population (66 1 & 2 13 ng/mL, median 632 ng/mL, range 210-1009 ng/mL) as compared to the controls (433 k 139 ng/mL, median 420 ng/mL, range 237-692 ng/mL).
As illustrated in Figure 4 , IGF-I levels negatively correlated with IGF-BP25 for both the control (r = -0.63, p = 0. children. IGF-I1 positively correlates with IGF-BP53 for both the control (r = 0.75, p = 0.003) and CRF (r = 0.78, p = 0.0004) populations.
Molar ratios. To further investigate the molecular interrelationships of the IGF and the IGF-BP, the measured concentrations of these peptides were converted to molar concentrations and compared. Mol wt used for the conversions were 7.5 kD for IGF-I and II,25 kD for IGF-BP25 and 53 kD for IGF-BP53.
The ratio of the molar concentrations of IGF-I to IGF-BP25 was 5.42 f 7.58 for the controls and 1.16 f 1.71 for the CRF children. IGF-I1 to IGF-BP25 molar ratios were 8.66 f 9.94 and 2.7 1 f 3.14, respectively. Total IGF to IGF-BP25 molar ratios were 14.44 f 17.48 for the controls and 3.88 + 4.76 for the CRF children. All three ratios were significantly decreased ( p < 0. 0 1) for the CRF subjects relative to their controls. As shown in Figure 5a , log (total mol IGF/mol IGF-BP25) showed a significant increase with age for both the control (r = 0.79, p = 0.0007) and CRF children (r = 0.62, p = 0.01).
IGF-I to IGF-BP53 molar ratios were 0.59 -t 0.25 for the controls and 0.33 f 0.24 for the CRF children, and IGF-I1 to IGF-BP43 molar ratios were 1.16 + 0.22 and 1.01 + 0.2 1, respectively. Total IGF to IGF-BP53 molar ratios were 1.76 f 0.30 for the controls, and 1.34 f 0.42 for the CRF children. All three ratios were significantly ( p < 0.05) decreased for the CRF subjects relative to their controls. As shown in Figure 5b , the total IGF to IGF-BP53 molar ratios increased with age for both the normals (r = 0.68, p = 0.01) and CRF (r = 0.82, p = 0.0001). Furthermore, as shown in Figure 6 , the total IGF to IGF-BP53 molar ratios correlated with total IGF levels for both the controls (r = 0.86, p = 0.0002) and CRF (r = 0.85, p = 0.00003) subjects.
DISCUSSION
Early studies of the low mol wt unsaturated IGF-binding protein were limited by the lack of purified protein, and quantitation relied upon assays of IGF-binding activity. These studies have shown that the low mol wt circulating IGF-binding activity increases in the presence of growth hormone deficiency (2 1) and in CRF (8) . Recent progress, including the investigations reported here, allow direct quantitation of this IGF-binding protein.
Our IGF-BP25 RIA is similar to that developed in other laboratories, and we have found that levels in normal nonfasting children and adults (Lee PDK, Powell DR, unpublished data) are comparable to levels reported by others (22, 24, 25) , IGF-BP25 levels for large groups of fasting children have not been published. To avoid the reported diurnal variation of circulating IGF-BP25 levels (25) , all samples used in the study and control populations were collected in the morning after an overnight fast.
As we have previously reported for the childhood CRF and matched control subjects (8), the IGF-I levels do not differ between the two groups, and the IGF-I1 levels are significantly elevated for the CRF group. It is of interest that both IGF-I and IGF-I1 show an age-related increase with age, whereas previous studies have shown no relationship of IGF-I1 levels with age (26) . This may be due to the controlled conditions of sampling, although we have no direct evidence for this.
Our data show elevated levels of IGF-BP25 in children with CRF and growth retardation as compared to age and sex-matched controls. These findings are in agreement with previous reports of elevated levels of IGF-BP25 in adults with uremia associated with diabetes mellitus and in a limited population of children with CRF (14, 15) . The close correlation with IGF-binding activity and the size fractionation of the immunoreactivity indicates that the elevated levels represent an actual increase of bioactive IGF-BP25 rather than simply decreased clearance of immunoreactive, biologically inactive, metabolized protein. Furthermore, although the molar ratios of IGF to IGF-BP25 increased peripubertally for all three pediatric groups studied, the ratios were significantly lower for the CRF group. Although the duration of fasting before sample collection was not strictly controlled, the variability that might result from minor variations in the duration of overnight fasting would not explain the large between-group differences in IGF-BP25 levels observed.
The possible physiologic significance of the elevated IGF-BP25 levels is suggested by previous investigations of this protein.
Although IGF-BP25 has been reported to enhance the mitogenic effect of IGF-I for fibroblasts (27) , this protein inhibits IGF bioactivity in most other systems studied. Unsaturated low mol wt IGF-BP (1 1) or purified IGF-BP25 (28, 29) leads to inhibition of IGF receptor binding and IGF-stimulated mitogenesis and cell metabolism in vitro. Infusion of IGF-I into rodents and humans leads to an acute insulin-like effect, followed by a decline in this effect coincident with the association of IGF-I with serum fractions containing IGF-BP25 (30, 3 1) . Furthermore, infusion of mutant forms of IGF-I that bind to the IGF-I receptor but not to IGF-BP25 leads to a prolongation of the insulin-like effects (32, 33) . Addition of purified IGF-BP25 to chick embryo cartilage in vitro leads to inhibition of IGF-I stimulated DNA and proteoglycan synthesis (34) . In view of these observations, our data suggest that elevations of the IGF-inhibitory protein in CRF may contribute to the growth retardation associated with this disorder. The possible physiologic effects of elevated IGF-BP25 in adults with CRF is uncertain, although inhibition of IGF action may lead to a negative effect on nitrogen balance (35) .
The mechanism for the IGF-BP25 elevation is uncertain, and may be related to an effect of renal failure on either metabolism and clearance or production of this protein. To gain further insight into this question, we further analyzed our data to determine whether physiologic interrelationships of age, IGF, and IGF-BP25 are altered.
In growth hormone deficiency, growth retardation is associated with decreased IGF-I levels and increased serum IGF-binding activity, indicating an inverse relationship between IGF-I and unsaturated IGF-binding activity (9, 21) , Povoa et al. (14) reported a similar negative correlation between IGF-I levels and IGF-BP25 levels by RIA in acromegalics, but not adults with diabetic nephropathy.
Our data confirm an inverse correlation of IGF-I and IGF-BP25, and we speculate that this may be mediated by growth hormone. An inverse relationship between IGF-I1 and IGF-BP25 was also observed. Furthermore, an inverse correlation of age with IGF-BP25 was observed for both populations. Inasmuch as the levels of IGF-I and IGF-I1 are not decreased in CRF, these results suggest that the abnormally high levels of IGF-BP25 may be due to a defect in the the metabolism and clearance of this protein. Alternatively, undefined physiologic mechanisms that account for the inverse relationship of IGF and IGF-BP25 may be disrupted, leading to incomplete feedback and a relative overproduction of IGF-BP25.
Nutritional status may play a role in the elevated IGF-BP25 levels observed for the CRF patients. Overnight and 24-h fasting in normal subjects leads to elevated IGF-BP25 levels, and accounts for the usual diurnal variation (36, 37) .Elevated IGF-BP25 levels have also been reported in anorexia nervosa (24) . Although IGF-I and IGF-I1 levels are usually low in malnutrition (38) , this relationship does not hold for malnutrition associated with renal failure (39) . However, the degree of IGF-BP25 elevation for our study population far exceeds that reported for other more severely malnourished individuals with anorexia nervosa; and the degree of caloric deficiency for our CRF study population showed no correlation with IGF-BP25 levels. The three children with CRF and normal nutritional intake (2 100% recommended daily allowance) had significantly greater IGF-BP25 levels as compared to their matched controls. Therefore, the role of malnutrition in elevating IGF-BP25 levels in CRF remains unresolved.
Other investigators have shown that insulin decreases circulating IGF-BP25 levels (40) . Insulin levels are usually increased in CRF, probably secondary to a postreceptor defect leading to insulin resistance (41). Our finding of elevated IGF-BP25 levels in CRF suggests, therefore, that the expected inverse relationship of insulin and IGF-BP25 levels may be abnormal. However, we were not able to address this possibility directly, because.insulin levels were not determined.
IGF-BP53 is an IGF-binding protein derived from the 150-to 200-kD IGF/IGF-binding protein complex, and is distinct from IGF-BP25 (23, 42) . The primary structure of IGF-BP53, based on cDNA cloning, indicates that it has approximately 33% amino acid sequence homology with IGF-BP25, including 18 conserved cysteineresidues (43). Levels of IGF-BP53 peak in midpuberty, and are relatively low in early childhood and adulthood (20) . Elevated levels of IGF-BP53 have been reported in adults with CRF (20) , and our current report extends this observation to children.
Serum IGF-BP53 levels did not positively correlate with IGF-BP25 or IGF-binding activity, suggesting different regulatory mechanisms for these two proteins. Unlike IGF-BP25, serum IGF-BP53 is derived from an IGF-saturated fraction of serum (20) , and may not function as a dynamic inhibitor of circulating IGF action; although we certainly cannot exclude the possibility that it may inhibit IGF action through another mechanism. Levels of IGF-BPS3 should reflect circulating IGF levels, whereas the ratio of IGF to IGF-BP53 should remain constant with relation to age and IGF levels. However, we observed that the ratio of IGF to IGF-BPS3 increased with both age and IGF levels for the CRF and control children. This apparent change in the valence of the saturated large mol wt complex is unexplained, but may be related to the accumulation of inactive immunoreactive metabolites of the IGF-BPS3 protein in the younger children. The physiologic significance of the elevated IGF-BP53 levels and consequent decreased IGF to IGF-BP53 ratios in CRF is also uncertain, and deserves future investigation.
In summary, we have found elevated levels of immunoassayable IGF-BP25 in children with CRF as compared to healthy age-and sex-matched controls. The data presented suggests that this is due to accumulation of a bioactive form of this IGFinhibitory protein in the presence of disrupted physiologic interrelationships. These data support a role for IGF-BP25 in the growth retardation associated with CRF. We also confirmed that IGF-BP53 is elevated in CRF, although the physiological significance of this latter observation remains uncertain.
